Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Juno, Editas Form Cell Therapy Pact
by Lisa M. Jarvis
June 1, 2015
| A version of this story appeared in
Volume 93, Issue 22
In a pact that combines two hot technologies, the T-cell-based therapies developer Juno Therapeutics will pay $25 million to Editas Medicine to use its CRISPR/Cas9 gene-editing capabilities. Editas also will get $22 million in R&D support over the next five years. Juno genetically engineers a cancer patient’s T cells to detect and kill diseased cells. Gene-editing technology from Editas could help broaden the effectiveness of the engineered T cells beyond certain blood cancers to solid tumors.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X